Who Paid My Doc
Jennifer Killion
Internal Medicine Ames,, IA
NPI 1649269648 CMS profile 467238
1215 Duff Ave, Ames,, IA 50010
General payments
$0
Research payments
$0
Ownership & investment interest
$0
The CMS Open Payments record contains no reported payments to Jennifer Killion of Ames,, IA.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
Prescribing to Medicare patients
Part D · data year 2024 · 161 drugsPart D claims
12,425
Drug cost
$854,095
Branded share of claims
20.6%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 277 | $201,985 | |
| Ozempic Semaglutide | Brand | 146 | $182,484 | |
| Trulicity Dulaglutide | Brand | 72 | $68,955 | |
| Jardiance Empagliflozin | Brand | 61 | $49,775 | |
| Januvia Sitagliptin Phosphate | Brand | 26 | $37,875 | |
| Mounjaro Tirzepatide | Brand | 27 | $31,325 | |
| Rybelsus Semaglutide | Brand | 18 | $25,250 | |
| Xarelto Rivaroxaban | Brand | 21 | $21,741 | |
| Combivent Respimat Ipratropium/Albuterol Sulfate | Brand | 28 | $14,120 | |
| Myrbetriq Mirabegron | Brand | 27 | $11,302 |
The 10 drugs with the highest cost, of 161 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 127 billing codesPaid by Medicare
$288,740
Medicare patients
647
Services billed
9,514
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 70% | |
| Arthritis | 40% | |
| Diabetes | 23% | |
| Chronic kidney disease | 20% | |
| Ischemic heart disease | 18% | |
| Atrial fibrillation | 17% | |
| Osteoporosis | 17% | |
| Depression | 16% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, denosumab, 1 mg J0897 | Office | 26 | 2,100 | $43,309 |
| Sarscov2 vac 50 mcg/0.5ml im 91322 | Office | 165 | 186 | $28,125 |
| Vaccine for influenza for injection into muscle 90662 | Office | 135 | 139 | $11,265 |
| Pcv20 vaccine im 90677 | Office | 19 | 19 | $5,494 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 | Office | 14 | 59 | $54 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Other Internal Medicine in Iowa
Related records
Internal Medicine in Iowa
Practitioners in the same specialty and state, ranked by reported value.
All Internal Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Iowa
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.